Venture Visionary Partners LLC Has $722,000 Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Venture Visionary Partners LLC trimmed its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 11.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,053 shares of the medical research company’s stock after selling 381 shares during the period. Venture Visionary Partners LLC’s holdings in Charles River Laboratories International were worth $722,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Charles River Laboratories International by 0.5% during the third quarter. Vanguard Group Inc. now owns 5,953,860 shares of the medical research company’s stock worth $1,166,837,000 after acquiring an additional 29,482 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Charles River Laboratories International by 35.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock worth $505,821,000 after acquiring an additional 653,790 shares during the period. State Street Corp raised its holdings in shares of Charles River Laboratories International by 1.8% during the second quarter. State Street Corp now owns 2,091,017 shares of the medical research company’s stock worth $439,636,000 after acquiring an additional 37,816 shares during the period. Kayne Anderson Rudnick Investment Management LLC increased its stake in Charles River Laboratories International by 3.9% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,746,101 shares of the medical research company’s stock valued at $342,201,000 after buying an additional 64,981 shares during the last quarter. Finally, Moneta Group Investment Advisors LLC acquired a new stake in Charles River Laboratories International in the 4th quarter valued at $298,877,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have issued reports on CRL. Robert W. Baird lifted their price target on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a research note on Thursday, February 15th. Argus lifted their price target on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, March 18th. TheStreet upgraded shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $253.10 on Friday. The company has a market capitalization of $13.04 billion, a price-to-earnings ratio of 27.48, a PEG ratio of 1.98 and a beta of 1.40. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. The company has a 50-day simple moving average of $249.73 and a 200 day simple moving average of $218.39. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.39 by $0.07. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. Charles River Laboratories International’s revenue was down 7.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.98 EPS. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Shannon M. Parisotto sold 5,882 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP William D. Barbo sold 4,050 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the sale, the vice president now directly owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,932 shares of company stock valued at $3,693,663. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).